Swedish Orphan ADR (SWTUY) 12.4500 $SWTUY Psoriatic

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Swedish Orphan ADR (SWTUY) 12.4500 $SWTUY

Psoriatic Arthritis Pipeline Report 2015 - 28 Companies & 25 Drug Profiles
M2 - Fri Jul 10, 3:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9fbkq/psoriatic) has announced the addition of the "Psoriatic Arthritis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Psoriatic Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - AbGenomics International, Inc. - Alder Biopharmaceuticals Inc. - Amgen Inc. - Avesthagen Limited - Biocon Limited - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Coherus BioSciences, Inc. - Covagen AG - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Genor BioPharma Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - Innovent Biologics, Inc. - Johnson & Johnson - Kineta, Inc. - Mabion SA - Momenta Pharmaceuticals, Inc. - Novartis AG - Oncobiologics, Inc. - Panacea Biotec Limited - Pfizer Inc. - Sandoz International GmbH - Swedish Orphan Biovitrum AB - Therapeutic Proteins International, LLC - UCB S.A. Drug Profiles - abatacept (recombinant) - AbGn-168H - ABT-122 - adalimumab biosimilar - anakinra (recombinant) - apremilast - bimekizumab - brodalumab - clazakizumab - COVA-322 - dalazatide - etanercept biosimilar - golimumab - golimumab biosimilar - guselkumab - IBI-303 - IBPM-004AM - IBPM-005IX - infliximab biosimilar - INV-17 - itolizumab - ixekizumab - Peptide to Inhibit CD44 for Rheumatoid and Psoriatic Arthritis - secukinumab - tofacitinib For more information visit http://www.researchandmarkets.com/research/s9fbkq/psoriatic
PFE: 34.36 (+0.50), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), BMY: 69.27 (+1.38), MNTA: 21.76 (+0.49), CHRS: 33.06 (+3.19), JNJ: 99.53 (+1.13), ALDR: 49.86 (+3.96), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20), CELGZ: 2.15 (+0.14)

Psoriatic Arthritis Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jul 09, 8:30PM CDT
The report "Psoriatic Arthritis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Psoriatic Arthritis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/psoriatic-ar...eport.html .
JNJ: 99.53 (+1.13), ALDR: 49.86 (+3.96), PFE: 34.36 (+0.50), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), BMY: 69.27 (+1.38), NVS: 103.22 (+3.20), CHRS: 33.06 (+3.19), CELGZ: 2.15 (+0.14)

Resolutions from Sobi's Annual General Meeting
Thomson Reuters ONE - Tue Jun 30, 9:16AM CDT
The Swedish Orphan Biovitrum AB (publ) (Sobi) Annual General Meeting (AGM) convened earlier today in Stockholm and voted in favour of the resolutions proposed at the meeting, including:

European Commission approves Orfadin(R) oral suspension
Thomson Reuters ONE - Mon Jun 29, 1:00AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that the European Commission has approved the oral suspension formulation of Orfadin(R) (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1) as of 19 June 2015. HT-1 is a rare genetic disease that affects infants and children. It is progressive and may result in liver and kidney failure and can be fatal if untreated.

Invitation - Presentation of Sobi's second quarter 2015
Thomson Reuters ONE - Fri Jun 26, 1:30AM CDT
On 16 July, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the second quarter 2015.

Sobi's 2012 Long-Term Incentive programme meets all objectives
Thomson Reuters ONE - Fri Jun 12, 1:00AM CDT
Swedish Orphan Biovitrum AB's (publ) (Sobi) Board of Directors today announced that the company's 2012 Long-Term Incentive programme met the objectives set and has vested in full. The total number of shares awarded to Sobi employees enrolled in the 2012 programme is 583,139.

Sobi Board of Directors terminates discussions regarding non-binding proposal
Thomson Reuters ONE - Mon Jun 08, 1:01AM CDT
On 27 April 2015 the Board of Swedish Orphan Biovitrum AB (publ) (Sobi) confirmed that it had received a preliminary and conditional non-binding proposal in relation to a possible offer for all shares issued by the company. The Board of Directors of Sobi has terminated discussions regarding this proposal. Sobi will continue to focus on preparations for the upcoming planned launch of Elocta and Alprolix and on building value through its diverse and growing portfolio.

Sobi's partner Biogen submits marketing authorisation application for Alprolix(R) (rFIXFc) in Europe
Thomson Reuters ONE - Thu Jun 04, 7:31AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that partner Biogen has submitted a Marketing Authorisation Application (MAA) for Alprolix (rFIXFc) to the European Medicines Agency (EMA). Sobi has an opt-in right to assume final development and commercialisation of Alprolix in Europe, Russia, certain countries in the Middle East, and North Africa. The MAA filing with the EMA coupled with the receipt of the opt-in data package, triggers the formal opt-in right, for Sobi to exercise its option in accordance with the collaboration agreement.

Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)
Thomson Reuters ONE - Wed May 27, 1:03AM CDT
The shareholders in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, are hereby summoned to the annual general meeting (the "Meeting" , to be held on Tuesday 30 June 2015 at 2.00 p.m. in Wallenbergsalen at Kungliga Ingenjorsvetenskapsakademien (IVA), Grev Turegatan 16, Stockholm, Sweden.

Idiopathic Juvenile Arthritis (Still's Disease) Therapeutics Pipeline Review 2015
M2 - Wed May 06, 8:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vkzw3z/idiopathic) has announced the addition of the "Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlphaMab Co., Ltd - Biocon Limited - Epirus Biopharmaceuticals, Inc. - Genor BioPharma Co., Ltd. - Mabion SA - Oncodesign SA - Panacea Biotec Limited - Pfizer Inc. - Sandoz International GmbH - Swedish Orphan Biovitrum AB - UCB S.A. For more information visit http://www.researchandmarkets.com/research/vkzw3z/idiopathic
PFE: 34.36 (+0.50)

Sobi publishes its Report for the First Quarter 2015
Thomson Reuters ONE - Wed May 06, 1:33AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the first quarter 2015. Revenues for the quarter totalled SEK 865 M (573). All parts of the business contributed to the result with ReFacto(R), Orfadin(R) and Kineret(R) delivering strong performance.

Early treatment and a longer life - new Orfadin formats meet new patient needs
Thomson Reuters ONE - Mon May 04, 7:31AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the oral suspension formulation and the 20 mg capsule of Orfadin (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1). HT-1 is a rare genetic disease that affects infants and children; it is progressive in nature, may result in liver and kidney failure and can be fatal if untreated.

Invitation - Presentation of Sobi's first quarter 2015
Thomson Reuters ONE - Thu Apr 30, 1:00AM CDT
On 6 May, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the first quarter 2015.

Sobi's Board of Directors postpones Annual General Meeting of Shareholders
Thomson Reuters ONE - Wed Apr 29, 1:06AM CDT
On 27 April 2015 the Board of Directors of Swedish Orphan Biovitrum AB (publ) (Sobi) confirmed that it had received a preliminary and conditional non-binding proposal in relation to a possible offer for all shares issued by the company. There can be no certainty that an offer will be made, nor as to the terms of any such offer.

Statement regarding recent speculation
Thomson Reuters ONE - Mon Apr 27, 1:06AM CDT
The Board of Swedish Orphan Biovitrum AB (publ) notes the recent speculation in the press and elsewhere regarding a potential acquisition of the company.

Swedish Orphan Biovitrum AB (publ) : Sobi publishes Annual Report 2014
Thomson Reuters ONE - Wed Apr 15, 6:01AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today published its Annual Report for 2014, themed "We have a story to tell", on the company's website, www.sobi.com.

Sobi publishes its Report for the Fourth Quarter and Full Year 2014
Thomson Reuters ONE - Thu Feb 19, 1:02AM CST
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the fourth quarter and full year 2014. Revenues for the year totalled SEK 2,607 M (2,177), an increase of 20 per cent. Revenues in the fourth quarter were 15 per cent higher compared to the previous year. All parts of the business contributed to the result with Orfadin(R) and the Partner Products portfolio delivering strong performance.

Invitation - Presentation of Sobi's fourth quarter and full year results 2014
Thomson Reuters ONE - Thu Feb 12, 1:00AM CST
On 19 February, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the fourth quarter and full year 2014.

BioSpecifics Technologies wins approval for XIAPEX in the EU for treating Peyronie's Disease
M2 - Tue Feb 03, 5:16AM CST
Biopharmaceutical company BioSpecifics Technologies (NasdaqGM:BSTC) reported on Monday the receipt of approval by the Swedish Orphan Biovitrum AB (Sobi) from the EU Commission to market XIAPEX for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees.
BSTC: 50.96 (-0.51)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

KuCoin Unveils $1.1M USDT Black Friday Bonanza

Updated Category News Views 110

KuCoin's Festive Fireworks: Black Friday Bonanza Sometimes the crypto world feels like a carnival, and KuCoin's latest act is the $1.1 million USDT prize pool, rolling out as part of its 'Tis The Season holiday campaign. A move that matches the glitz of Tomorrowland Winter experiences, adding more sparkle to the crypto stage. Behind the Scenes of the KuCoin-Tomorrowland...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 88

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 72

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 43

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 33

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
Christian Faith: Navigating Spiritual Pitfalls Wisely

Updated Category News Views 13

Taking a Deep Look at Christian Faith If you think faith is as simple as saying a few prayers and checking church attendance off the list, well, think again. G. Joseph Johnson, in his thought-provoking tome "Roads, Ditches, Traps, and Snares," believes that faith is a journey filled with twists, turns, and yes, a few traps. This book is a sort of roadmap for Christians,...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 98

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 98

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 438

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Nevada Expands Rural Youth Mental Health Access

Updated Category News Views 72

Nevada's Rural Mental Health Crisis When you're navigating the barren stretches of rural Nevada, the scenic views can be breathtaking. But for many families, finding basic services like mental health care is as challenging as striking water in the desert. Cartwheel Care has taken the bull by the horns with their latest initiative to bridge this glaring gap. Partnering...

Continue Reading

Top 5 Most Recently Viewed Articles

Bitcoin's Critical Moment: Navigating Possible Downtrends

Updated Category News Views 58

Understanding Bitcoin's Potential Death Cross There's a lot of chatter right now about a possible death cross for Bitcoin, which has fascinated traders and investors alike. This event happens when a short-term moving average, like the 50-day, dips below a long-term moving average, such as the 200-day. This intersection suggests a potential bearish trend in price movement....

Continue Reading
Calamos Enhances Investment Options with New ETF Offering

Updated Category News Views 175

Calamos Launches Innovative ETF for S&P 500 Investors The new Calamos S&P 500 Structured Alt Protection ETF offers an enticing proposition for investors seeking exposure to the S&P 500 while safeguarding against potential downturns. This ETF, identified as CPSF, aims to provide 100% downside protection over a one-year timeline, allowing investors to navigate market...

Continue Reading
Rising Global Defense Expenditure Transforms Drone Technologies

Updated Category News Views 273

Transforming Defense with Advanced Drone Solutions The military drone market is experiencing remarkable growth as governments around the world respond to rising geopolitical tensions. The increase in global defense budgets is fueling investment in unmanned aerial systems (UAS), propelling innovation and expansion in the sector. The Current State of the Military Drone...

Continue Reading
Soft N Dry Launches Innovative Diaper Connection Programme

Updated Category News Views 115

Enhancing Retail Connections for Sustainability Soft N Dry Diapers Corp. (NASDAQ: SDC) is taking a significant step in enhancing its relationships with retailers through the launch of its Retail Consumer Connection Programme (RCCP). The initiative is designed to give retailers the support they need to stock the groundbreaking TreeFree Diaper™, which is driving consumer...

Continue Reading
Understanding Truck Accident Settlements in Memphis

Updated Category News Views 27

Delving into Truck Accident Settlement Timelines Out there in Memphis, timing a truck accident settlement isn't exactly like clockwork work. When it comes to getting your compensation, the timeline varies as widely as a duck hunting trip—sometimes you come home with a basketful, sometimes it’s empty. It might be a quick couple of months or drag on past a year, and...

Continue Reading